StocksCara Therapeutics CARA

CARA

Cara Therapeutics

18.09 0.01 (0.06%)
Delayed Prices By NASDAQ, in USD Market Closed
Trade
S
18.08
B
18.14

Overview

Prev Close18.09
Day's Range16.65 - 18.09
52 Week Range8.87 - 22.55
Average Volume (3m)506.8K
1-Year Return30.45%
Beta1.2128
Market Cap902.27M
P/E Ratio223.61
Revenue135.08M
EPS0.0809
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Chart times in UTC
Industry Biotechnology
CEO Derek T. Chalmers, PhD
Employees 80

FINANCIAL SUMMARY

For the quarter ended 30/9/2020, Cara Therapeutics 's revenues increased by 64.47% and amounted to 9.27M. Net income increased by 34.14% to -16.51M. Net assets decreased by 9.28% to 127.85M and EPS increased from -0.54 to -0.35.
CARA's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
N/A
Net Profit Margin
-14,812.64%
Operating Margin
3.99%
Return On Investment
-57.59%
12/19
03/20
06/20
09/20
Total Revenue
4.51M
8.09M
5.63M
9.27M
Gross Profit
N/A
N/A
N/A
N/A
Operating Income
-29.97M
-30M
-25.88M
-17.02M
Net Income
-28.61M
-28.92M
-25.07M
-16.51M